Compare TBPH & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | PDM |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | TBPH | PDM |
|---|---|---|
| Price | $18.73 | $8.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $27.80 | $9.25 |
| AVG Volume (30 Days) | 601.0K | ★ 670.7K |
| Earning Date | 11-10-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 1.47% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | $80,327,000.00 | ★ $565,372,000.00 |
| Revenue This Year | $70.78 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.19 | ★ N/A |
| Revenue Growth | ★ 27.12 | N/A |
| 52 Week Low | $7.90 | $5.46 |
| 52 Week High | $20.33 | $9.55 |
| Indicator | TBPH | PDM |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 50.96 |
| Support Level | $18.39 | $8.52 |
| Resistance Level | $20.32 | $8.85 |
| Average True Range (ATR) | 0.87 | 0.28 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 53.71 | 53.54 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.